GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Minapharm Pharmaceuticals (CAI:MIPH) » Definitions » 14-Day RSI

Minapharm Pharmaceuticals (CAI:MIPH) 14-Day RSI : 65.52 (As of Dec. 15, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Minapharm Pharmaceuticals 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-12-15), Minapharm Pharmaceuticals's 14-Day RSI is 65.52.

The industry rank for Minapharm Pharmaceuticals's 14-Day RSI or its related term are showing as below:

CAI:MIPH's 14-Day RSI is ranked worse than
92.33% of 1095 companies
in the Drug Manufacturers industry
Industry Median: 48.1 vs CAI:MIPH: 65.52

Competitive Comparison of Minapharm Pharmaceuticals's 14-Day RSI

For the Drug Manufacturers - Specialty & Generic subindustry, Minapharm Pharmaceuticals's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Minapharm Pharmaceuticals's 14-Day RSI Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Minapharm Pharmaceuticals's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Minapharm Pharmaceuticals's 14-Day RSI falls into.



Minapharm Pharmaceuticals  (CAI:MIPH) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Minapharm Pharmaceuticals  (CAI:MIPH) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Minapharm Pharmaceuticals 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Minapharm Pharmaceuticals's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Minapharm Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
El-Bardissi Street, 2T Takseem Asmaa Fahmy Street, Heliopolis, Cairo, EGY
Minapharm Pharmaceuticals is a company whose purpose is to produce medicines and chemicals. medical supplies. cosmetics, veterinary medicines, dental supplies, and the production of dietary supplements and herbal medicines. It produces drugs for many segments such as biogenetics, orthopedic, ophthalmology, miscellaneous, dermatology, gastroenterology, cardiology, and uro-gynaecology lines.

Minapharm Pharmaceuticals Headlines

No Headlines